OCGN Stock Analysis: Buy, Sell, or Hold?
OCGN - Ocugen, Inc. Common Stock
$1.28
0.04 (3.23%)
â˛
5d:
+4.07%
30d:
-12.93%
90d:
-11.11%
WAIT
LOW Confidence
Analysis Updated: Aug 7, 2026 12:00 AM ET
Earnings: Aug 06, 2026
0d
Get Alerted When OCGN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: OCGN is fairly priced but lacks strong directional signals. At 0% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: OCGN is fairly priced but lacks strong directional signals. At 0% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: OCGN is currently trading at $1.28, which is considered slightly low relative to its 30-day fair value range of $1.24 to $1.48. From a valuation perspective, the stock is trading at a discount (Forward PE: -5.5) compared to its historical average (40.6). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, OCGN is in a strong downtrend. Immediate support is located at $1.17, while resistance sits at $1.33. The stock is showing strong short-term momentum, up 3.2% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $12.17 (+850.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, OCGN is in a strong downtrend. Immediate support is located at $1.17, while resistance sits at $1.33. The stock is showing strong short-term momentum, up 3.2% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $12.17 (+850.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$1.24 -
$1.48
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
89.0%
Protect Your Profits
Holding OCGN? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.2%)
- BULLISH: Trading 850.5% below Wall St target ($12.17)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 52/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.24 -
$1.48
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$1.17
Resistance Level
$1.33
Current Trend
Strong Downtrend
Technical data as of
Aug 7, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.49
Wall Street Target
$12.17
(+850.5%)
Revenue Growth (YoY)
3.5%
PE vs Historical
-5.5 vs 40.6
CHEAP
Share & Embed Analysis
Last updated: August 08, 2026 5:27 AM ET
Data refreshes hourly during market hours. Next update: 6:27 AM
Data refreshes hourly during market hours. Next update: 6:27 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is OCGN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$416 | 57 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$87 | 54 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$196 | 48 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$108 | 60 HOLD |
|
CRNX
Crinetics PharmaceuticalâĻ |
STRONG BUY
17 analysts |
$86 | 46 HOLD |
Advanced OCGN Option Strategies
Professional options setups generated by AI based on today's OCGN price and gamma walls.
